Combination therapy for relapsed natural killer T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a combination of three treatments for a rare type of lymphoma called NKTCL that has come back or not responded to prior therapy. The treatments include a pill (selinexor), an immune-boosting drug (anti-PD-1 antibody), and a chemotherapy combination (P-GemOx). The goal is to see if this combination can help control the lymphoma and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called natural killer/T-cell lymphoma (NKTCL) affecting the nose or nasal area.
- You must have already received a standard chemotherapy that includes asparaginase.
- You must be between 14 and 75 years old.
- You must have at least one tumor or lymph node that can be measured on a scan.
- Your overall health should be good enough that you can do light or active daily tasks (ECOG score 0-2).
- Your liver, kidney, and blood counts must be within a certain safe range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.